drugset / Trial / NCT03485846
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to confirm that combination of Narlaprevir, Ritonavir and Daclatasvir is safe and highly effective regimen in treatment-naїve patients with chronic hepatitis C (HCV) genotype 1b infection.
Timeline
- Start
- 2017-11-27
- Primary completion
- 2018-08-29
- Completion
- 2018-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclatasvir | Small molecule | 60 mg | Oral |
| Subject | Narlaprevir | Small molecule | 200 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |